

CITATION REPORT

List of articles citing

Treatment of refractory rheumatoid arthritis with a chimeric anti-CD4 monoclonal antibody. Long-term followup of CD4+ T cell counts

DOI: 10.1002/art.1780370610

Arthritis and Rheumatism, 1994, 37, 834-8.

Source: <https://exaly.com/paper-pdf/25059898/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
115	Treatment of murine lupus with CTLA4Ig. 1994 , 265, 1225-7		611
114	Innovative treatment approaches for rheumatoid arthritis. T-cell regulation. 1995 , 9, 653-71		6
113	Innovative treatment approaches for rheumatoid arthritis. Issues in clinical trials of biological agents. 1995 , 9, 825-35		2
112	Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1995 , 38, 151-60		819
111	A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1995 , 38, 1097-106		135
110	Emergence of oligoclonal T cell populations following therapeutic T cell depletion in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1995 , 38, 1242-51		83
109	Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. <i>Arthritis and Rheumatism</i> , 1995 , 38, 1581-8		96
108	CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study. <i>Arthritis and Rheumatism</i> , 1995 , 38, 1589-94		96
107	Side-effects from biologics in the therapy of rheumatic diseases. 1995 , 3, 379-388		1
106	Prospects of immunotherapy for rheumatoid arthritis. 1995 , 17, 178-85		3
105	Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. 1995 , 144, 195-223		179
104	Autoimmunity. 1995 , 7, 860-76		
103	Long-term survivors of human immunodeficiency virus type 1 infection. 1995 , 332, 1646-7; author reply 1647-8		0
102	Acute respiratory distress syndrome. 1995 , 332, 1648-9; author reply 1650		
101	Regeneration of T cells after chemotherapy. 1995 , 332, 1650-1; author reply 1652		3
100	Antiemetic properties of granisetron. 1995 , 332, 1653; author reply 1653-4		
99	Book Review:Sharing the Burden. 1995 , 332, 1654-1654		

98	Treatment of refractory juvenile chronic arthritis by monoclonal CD4 antibodies: a pilot study in two children. 1995 , 54, 846-9	8
97	Stratégies thérapeutiques au cours des maladies auto-immunes. 1996 , 7, 147-151	0
96	Biologic agents for the treatment of rheumatoid arthritis. <i>Rheumatic Disease Clinics of North America</i> , 1996 , 22, 117-32	2.4 5
95	Cytokine-Suppressive Anti-Inflammatory Drugs. 1996 , 6, 395-404	1
94	Section Review Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: The current status and future prospects for biological targeted therapies for rheumatoid arthritis. 1996 , 5, 819-828	4
93	Immunoregulatory circuits and potential treatment of connective tissue diseases. 1996 , 111, 348-54	8
92	Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens. <i>Arthritis and Rheumatism</i> , 1996 , 39, 52-6	57
91	Nondepleting anti-CD4 antibody treatment prolongs lung-directed E1-deleted adenovirus-mediated gene expression in rats. 1996 , 7, 2273-9	56
90	Antibody to gp39, the ligand for CD40 significantly inhibits the humoral response from Graves' thyroid tissues xenografted into severe combined immunodeficient (SCID) mice. 1996 , 6, 267-73	22
89	Drug treatment of rheumatic diseases in the 1990s. Achievements and future developments. 1997 , 53, 337-48	8
88	Tolerance to heart and kidney grafts induced by nondepleting anti-CD4 monoclonal antibody (RIB 5/2) versus depleting anti-CD4 monoclonal antibody (OX-38) with donor antigen administration. 1997 , 122, 213-9; discussion 219-20	11
87	Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. 1997 , 157, 61-72	206
86	Distinctions Between CD8+ and CD4+ T-Cell Regenerative Pathways Result in Prolonged T-Cell Subset Imbalance After Intensive Chemotherapy. 1997 , 89, 3700-3707	303
85	Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease. 1997 , 110, 158-66	44
84	Thymic aging and T-cell regeneration. 1997 , 160, 91-102	212
83	Cytokines and prostaglandins in immune homeostasis and tissue destruction in periodontal disease. 1997 , 14, 112-43	269
82	Effect of boar seminal immunosuppressive component on humoral immune response in mice. 1997 , 38, 106-13	4
81	A primatized MAb to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: in vitro and in vivo characterization of a MAb (IDEC-CE9.1) to human CD4. 1997 , 84, 73-84	32

80	[Pathogenesis of rheumatoid arthritis]. 1997 , 92, 347-53	1
79	T-cell regeneration: all repertoires are not created equal. 1997 , 18, 245-51	211
78	Biologic agents for treating rheumatoid arthritis. Concepts and progress. <i>Arthritis and Rheumatism</i> , 1997 , 40, 397-409	121
77	Suppression of collagen-induced arthritis through adenovirus-mediated transfer of a modified tumor necrosis factor alpha receptor gene. <i>Arthritis and Rheumatism</i> , 1997 , 40, 1662-9	93
76	[Anti-CD4 therapy in treatment of rheumatoid arthritis--have the die been cast?]. 1998 , 57, 320-5	2
75	Opportunities for future biological therapy in SLE. 1998 , 12, 529-41	4
74	Reply. <i>Arthritis and Rheumatism</i> , 1998 , 41, 2084-2085	1
73	Anti-CD4 monoclonal antibodies in rheumatoid arthritis. 1998 , 20, 261-73	10
72	Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma. 1998 , 352, 1109-13	136
71	Monoclonal antibodies to CD4. <i>Rheumatic Disease Clinics of North America</i> , 1998 , 24, 567-78	2.4 13
70	Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4. 1998 , 11, 53-62	60
69	Early recovery of CD4+ T lymphocytes in children on highly active antiretroviral therapy. Dutch study group for children with HIV infections. 1998 , 12, 2155-9	51
68	New therapeutic targets for rheumatoid arthritis. 1999 , 21, 49-59	10
67	Anti-T cell strategies in asthma. 1999 , 48, 516-23	35
66	Anti-proliferative effects induced by anti-CD4 human/murine chimeric antibody and murine anti-CD4 monoclonal antibody. 1999 , 19, 6-9	
65	Management of therapy-resistant rheumatoid arthritis. 1999 , 13, 737-52	3
64	Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1999 , 42, 2166-73	78
63	Suppression of systemic lupus erythematosus disease in mice by oral administration of kidney extract. 1999 , 13, 405-14	6

62	Differential effects of administration of a human anti-CD4 monoclonal antibody, HM6G, in nonhuman primates. 1999 , 92, 138-52	21
61	T cell dynamics in HIV-1 infection. 1999 , 73, 301-27	53
60	Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. 1999 , 103, 1391-8	255
59	Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients. 2000 , 39, 1139-46	44
58	Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. 2000 , 43, 595-604	109
57	Current treatment practice in immunosuppression. 2000 , 1, 1307-30	19
56	New treatment possibilities in rheumatoid arthritis. 2000 , 29, 73-84	9
55	Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. 2001 , 108, 250-7	183
54	Organ transplant specificity of tolerance to skin grafts with heart or kidney grafts plus nondepleting anti-CD4 monoclonal antibody (RIB 5/2) and intravenous donor alloantigen administration. 2001 , 98, 59-65	3
53	Pharmacotherapy of rheumatoid arthritis: an overview. 2001 , 62, 92-112	11
52	Potential biologic agents for treating rheumatoid arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2001 , 27, 445-91	2.4 15
51	Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. <i>Arthritis and Rheumatism</i> , 2001 , 44, 1998-2008	67
50	From bench to bedside: discovering rules for antibody design, and improving serotherapy with monoclonal antibodies. 2001 , 40, 724-38	30
49	Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial. 2002 , 41, 1142-8	43
48	Reconstitution of naive T cells during antiretroviral treatment of HIV-infected adults is dependent on age. 2002 , 16, 2263-6	31
47	Differential clinical efficacy of anti-CD4 monoclonal antibodies in rat adjuvant arthritis is paralleled by differential influence on NF-kappaB binding activity and TNF-alpha secretion of T cells. 2002 , 4, 184-9	15
46	The use of monoclonal antibodies to restore self-tolerance in established autoimmunity. 2002 , 31, 457-75, ix	6
45	Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1470-9	310

44	Advances in the management of psoriasis: monoclonal antibody therapies. 2002 , 41, 827-35	8
43	Donor-specific renal, but not cardiac, allograft tolerance promotes engraftment of the normally rejected rat skin graft. 2003 , 16, 713-720	1
42	T cell dynamics in HIV-1 infection. 2003 , 21, 265-304	439
41	Immune modulator studies in primates: the utility of flow cytometry and immunohistochemistry in the identification and characterization of immunotoxicity. 2003 , 31 Suppl, 111-8	17
40	TNF receptor gene therapy results in suppression of IgG2a anticollagen antibody in collagen induced arthritis. 2003 , 62, 707-14	37
39	[Biologic therapy of inflammatory bowel disease]. 2003 , 41, 1017-32	5
38	Adoptive Immunotherapy: Methods and Protocols. 2004 ,	
37	Monoclonal antibody-based strategies in autoimmunity and transplantation. 2005 , 109, 297-328	6
36	Emerging Therapies for Autoimmune Diseases. 2006 , 1063-1081	1
35	Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. 2007 , 109, 4655-62	168
34	Biologic therapies in rheumatology: lessons learned, future directions. 2007 , 6, 75-92	141
33	Nouvelles biothérapies immunosuppressives dans les transplantations d'organes. 2008 , 192, 883-894	
32	Protective versus pathogenic anti-CD4 immunity: insights from the study of natural resistance to HIV infection. 2009 , 7, 101	4
31	MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments. 2011 , 13, R177	17
30	Molecular characterization of woodchuck CD4 (wCD4) and production of a depletion monoclonal antibody against wCD4. 2013 , 56, 64-71	2
29	Role of human CD4 D1D2 domain in HIV-1 infection. 2013 , 42, 106-21	2
28	Treatment of Autoimmune Disease: Biological and Molecular Therapies. 2014 , 1221-1245	1
27	Foxp3+ T cells inhibit antitumor immune memory modulated by mTOR inhibition. 2014 , 74, 2217-28	29

26	Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells. 2016 , 30, 701-7	52
25	Immunotoxicology of Biopharmaceutics. 2018 , 826-851	
24	Preclinical Targeting of Human Acute Myeloid Leukemia Using CD4-specific Chimeric Antigen Receptor (CAR) T Cells and NK Cells. 2019 , 10, 4408-4419	17
23	Induction of donor specific transplantation tolerance to cardiac allografts following treatment with nondepleting (RIB 5/2) or depleting (OX-38) anti-CD4 mAb plus intrathymic or intravenous donor alloantigen. 1997 , 63, 284-92	34
22	Persistent long-term changes in lymphocyte subsets induced by polyclonal antibodies. 1997 , 64, 1432-7	116
21	The kinetics of tolerance induction by nondepleting anti-CD4 monoclonal antibody (RIB 5/2) plus intravenous donor alloantigen administration. 2000 , 69, 285-93	14
20	Distinctions Between CD8+ and CD4+ T-Cell Regenerative Pathways Result in Prolonged T-Cell Subset Imbalance After Intensive Chemotherapy. 1997 , 89, 3700-3707	11
19	Recent developments in the treatment of rheumatoid arthritis with targeted biological agents. 1997 , 2, 269-286	1
18	Omega-3 Polyunsaturated Fatty Acids and Rheumatoid Arthritis. 2000 ,	
17	Therapeutic anti-T-cell monoclonal antibodies. 2001 , 99-113	
16	Perspectives in targeted therapy. 2009 , 207-220	
15	Immunotoxicology of Biopharmaceutics. 2010 , 489-519	
14	Immunotoxicology of Biopharmaceutics?. 2014 ,	
13	The pathogenesis of rheumatoid arthritis and the development of therapeutic strategies for the clinical investigation of biologics. <i>Agents and Actions Supplements</i> , 1995 , 47, 1-21	0.2
12	T CELLS IN RHEUMATOID ARTHRITIS. <i>Rheumatic Disease Clinics of North America</i> , 1995 , 21, 655-674	2.4 23
11	Anti-Idiotypic Monoclonal Antibody (mAb) to Anti-CD4 mAb as Surrogate of Human CD4 Antigen (Ag) for Active Immunotherapy of Autoimmune Diseases. 1997 , 239-254	
10	Side-Effects from Biologics in the Therapy of Rheumatic Diseases. 1997 , 67-76	
9	T cells as secondary players in rheumatoid arthritis. 1998 , 1-18	

8 T cell directed therapies and biologics. **1998**, 189-199

7 Treatment of Systemic Lupus Erythematosus by Selective Inhibition of T-Cell Function. **1999**, 642-655

6 T-cell costimulation and other directed therapies. **2015**, 468-471

1

5 T-cell modulating antibodies in inflammatory bowel disease. 194-201

4 OX40-Fc Fusion Protein Alleviates PD-1-Fc-Aggravated Rheumatoid Arthritis by Inhibiting Inflammatory Response.. *Computational and Mathematical Methods in Medicine*, **2022**, 2022, 6244175

2.8

0

3 Lymphopenia and Mechanisms of T-Cell Regeneration. **2022**, 16, 302-311

1

2 STCP-1 (MDC) CC Chemokine Acts Specifically on Chronically Activated Th2 Lymphocytes and Is Produced by Monocytes on Stimulation with Th2 Cytokines IL-4 and IL-13. **1998**, 161, 5027-5038

67

1 Adenoviral Transfer of the Viral IL-10 Gene Periarticularly to Mouse Paws Suppresses Development of Collagen-Induced Arthritis in Both Injected and Uninjected Paws. **1999**, 162, 3625-3632

27